Fecal microbiota transplant program for ulcerative colitis
Official title: Screening Donors for a Fecal Microbiota Transplant Program in Ulcerative Colitis: Evaluating Efficacy and Long-term Effects. the FUEL Study
Run by Hamilton Health Sciences Corporation · NCT04926103 · Data updated 2026-11-12
This study is testing whether using fecal transplants from different donors can help people with active ulcerative colitis feel better and stay in remission.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Hamilton Health Sciences Corporation Academic / other |
| Drugs / interventions | infliximab |
| Locations | 1 site (Hamilton, Ontario) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | October 1, 2028 |
| Study ends | May 1, 2029 |
| Registry record updated | October 1, 2024 |
| Trial ID | NCT04926103 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and over with active ulcerative colitis as defined by specific Mayo scores.
✕Probably not a fit
Patients with severe UC requiring hospitalization or those participating in other intervention studies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to screen new donors for fecal microbiota transplants (FMT) to treat patients with active ulcerative colitis (UC). It will involve recruiting up to 200 patients who will receive FMT, with the goal of evaluating the effectiveness of different donors in inducing remission. The study will follow patients long-term to assess the potential for maintenance FMT to achieve sustained remission. The open-label design allows for real-time assessment of donor efficacy in a clinical setting.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatments for ulcerative colitis, improving patient outcomes and quality of life.
How similar studies have gone: Previous studies have indicated varying success with fecal microbiota transplants in UC, suggesting that while this approach has shown promise, the specific donor effect remains an area of ongoing investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged 18 or over 2. Active UC defined as a Mayo score (7) \>3 3. A Mayo endoscopic score (7) \>0 4. Females of child-bearing potential must be willing and able to use acceptable contraception as per Appendix III. II. b. Toxicity section of the Health Canada Guidance Exclusion Criteria: 1. Participating in another intervention study for UC 2. Unable to give informed consent 3. Severe comorbid medical illness 4. Severe UC requiring hospitalization. 5. Increase in medical therapy for UC in the last 12 weeks. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNF therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will also be permitted provided the dose of steroid is not increased again. Stable intake of probiotic therapy also permitted. 6. Antibiotic therapy in the last 30 days. 7. Pregnant women. 8. Patients with clinically significant hepatic dysfunction at the time of screening: ALT \> 5 times the upper normal range. 9. Patients with clinically significant renal dysfunction at the time of screening: serum creatinine \> 300 µmol/L 10. Any condition, in the opinion of the investigator, that the treatment may pose a health risk to the subject.
Where it's running
-
Hamilton Health Sciences / McMaster University
Hamilton, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Paul Moayyedi, MD — HHSC/McMaster
- Study coordinator: Melanie A Wolfe, CCRP
- Email: wolfe@hhsc.ca
- Phone: 9055212100
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Front-of-neck approaches for anterior cervical spine surgery and swallowing problems
This will see if the Smith-Robinson or strap-splitting front-of-neck approach causes fewer swallowing or voice problems for adults having anterior cervical spine surgery.
-
Precision dosing of oral ibuprofen to close PDA in very preterm newborns
This study will test whether adjusting oral ibuprofen doses for each very preterm baby using blood levels and echocardiograms helps close a patent ductus arteriosus more often than the standard fixed dose.
-
Radiation therapy followed by immune therapy and surgery for hepatocellular carcinoma
This trial tests whether adding durvalumab and tremelimumab to radiation therapy before surgery helps people with resectable liver cancer.
-
IVUS-guided revascularization for leg arteries in CLTI
This study tests whether using intravascular ultrasound (IVUS) during leg artery revascularization helps reduce major limb events and significant re-narrowing in adults with chronic limb-threatening ischemia.
-
Evaluating health literacy in older patients
This study is trying to see how well older patients understand health information compared to what their doctors think, to improve communication and care for those with multiple health issues.
-
Helping newcomer families in Hamilton access physical activity resources
This study is testing whether giving newcomer families in Hamilton better access to physical activities can help their kids aged 5 to 11 feel more confident and active over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.